{"disease":{"id":"lymphodepleting-chemotherapy","name":"lymphodepleting chemotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06383572","title":"Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}